New review sorts evidence from overgeneralizations
Image content: This image is available to view online.
View image online (https://assets.clevelandclinic.org/transform/e6f68632-0fd5-482e-bb27-177447880696/21-HVI-2104549_carbohydrate-grains-fiber_650x450_jpg)
21-HVI-2104549_carbohydrate-grains-fiber_650x450
When it comes to teasing out the effects of dietary carbohydrate intake on cardiometabolic health, the devil is very much in the details, and more details are needed for conclusions on some important questions. That’s an overarching message of a new evidence-based review of the topic published in Atherosclerosis (Epub March 27, 2021) by Cleveland Clinic cardiologist Leslie Cho, MD, and two European colleagues.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Carbohydrates have been vilified in the media over the past two decades, often due to overbroad generalizations not supported by evidence,” says Dr. Cho, Co-Section Head of Preventive Cardiology and Rehabilitation. “The recent prominence of high-protein diets for weight loss has fueled further confusion, leading too many people to overlook the essential role carbohydrates play in a healthy diet.”
Together with expert nutrition and health researchers from the Netherlands and Italy, Dr. Cho reviewed the latest evidence — almost exclusively from observational studies and meta-analyses of intervention studies — on the effect of fiber, whole grain and refined carbohydrates on the following:
They begin by noting that current understanding of carbohydrates’ health effects has been hindered by the traditional limitations of dietary recall studies and the fact that many studies to date have failed to differentiate among the various types of carbohydrates.
“Carbohydrates may be thought of in terms of complex versus simple and then further broken down into fiber, starches and sugar,” notes Dr. Cho, the paper’s corresponding author.
Accordingly, the paper proceeds to review the latest evidence from clinical studies in three main sections:
The review leads the authors to a number of conclusions, including the following:
Advertisement
“The quality of the carbohydrate dictates its effect on both cardiometabolic health and cardiovascular events,” observes Dr. Cho. “Moreover, individuals’ responses to dietary fiber interventions are likely determined by their initial microbial and/or metabolic phenotype. It’s becoming more and more clear that this is not a one-size-fits-all question.”
In fact, the review authors identify the impact of individual traits and lifestyle factors on the effectiveness of fiber interventions as a priority for future research. Another priority focus is the role played by regional and ethnic differences in various metabolic and clinical outcomes of the consumption of differing types of carbohydrates. And the authors note that because most data to date are from observational studies, definitive evidence on the benefits and adverse effects of various carbohydrate types is lacking.
The review authors note that the emergence of mobile app-enabled patient-entered diet data should help bolster the number and quality of dietary and intervention studies to start filling these knowledge gaps. “A revolution in dietary research may be at hand, thanks to the power of patient-entered data along with evolving insights into the impact of the gut microbiome,” says Dr. Cho.
In the meantime, despite the considerable remaining uncertainties, she believes there’s enough clarity to make a broad recommendation for present action. “At a global level, most people consume less than 20 grams of fiber daily while consuming a large quantity of refined carbohydrates,” Dr. Cho notes. “The current evidence fully justifies additional measures to enhance the amount and variety of fiber consumption worldwide while simultaneously reducing intake of refined carbohydrates.”
Advertisement
The review paper is available here.
Advertisement
Advertisement
They generally depend on the mutated gene, clone size and clinical setting
Large analysis adds to evidence that absolute diameter alone may miss vulnerable patients
Procedure places the center among only a handful worldwide to offer the minimally invasive approach
Phase 1 trial shows up to 97% decrease through 48 weeks with good tolerability
Post hoc ALPACA analysis boosts biological rationale for ongoing outcomes trial of lepodisiran
Durability findings propel potential one-time treatment approach to phase 1b testing
Practical takeaways for the reality of overlapping cardiovascular, kidney and metabolic disease
First prospective study shows early extubation and low vasoactive/inotropic medication use